RT Journal Article
SR Electronic
T1 PET/CT for restaging breast cancer – Impact on patient management and patient outcome
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 18P
OP 18P
VO 49
IS supplement 1
A1 Souvatzoglou, Michael
A1 Buck, Andreas
A1 Schmidt, Stefan
A1 Quante, Stefan
A1 Herrmann, Ken
A1 Scheidhauer, Klemens
A1 Glatting, G.
A1 Pauls, S.
A1 Schwaiger, Markus
A1 Reske, Sven
YR 2008
UL http://jnm.snmjournals.org/content/49/supplement_1/18P.4.abstract
AB 72 Objectives: The purpose of this study was to assess the diagnostic effectiveness of PET/CT for restaging breast cancer. Furthermore, impact on patient management and patient outcome was evaluated. Methods: In this prospective bi-center trial, 118 patients with a history of breast cancer and newly diagnosed increase of tumor markers or other clinical signs for recurrent disease were included. 60-90 min after iv-injection of FDG, pts underwent PET/CT imaging (PET 3min/bp, i.v. contrast diagnostic CT) using PET/CT scanners. Each PET/CT mode was evaluated seperately by two physicians blinded to other modalities’ results using a 5-point score. A consensus for final lesion characterisation was made for PET/CT. Follow up data are available in 87/118 pts. Imaging results were correlated to patient management and patient outcome (Logrank test). Results: PET/CT returned positive findings in 67% (79/118). Local recurrent breast cancer was observed in 14 pts (12%), metastases in lymph nodes in 42 (36%), in the lungs in 12 (10%), in pleura in 2 (2%), in liver in 17 (14%), in bone in 38 (32%) and in the adrenals in 4 pts (3%). PET negative lesions were found in 10% (12/118). So far there was a change of therapeutic management in 29/87 pts (33%). Furthermore, after mean follow-up of 3 years, in PET/CT negative pts median survival was not reached (>90% survivors), while in pts with a positive PET/CT scan, median survival was 3.3 years (p=0.013). Conclusions: In pts with breast cancer suspicious for having recurrent disease, PET/CT detected local or distant recurrence in 67% and had a major impact on patient management. Our study also shows the prognostic potential of PET/CT for restaging breast cancer.